INVO BioScience Inc. (INVO) Financial Statements (2025 and earlier)
Company Profile
Business Address |
5582 BROADCAST COURT SARASOTA, FL 34240 |
State of Incorp. | NV |
Fiscal Year End | December 31 |
Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 943 | 475 | 232 | 1,056 | 112 | 2,188 | |||
Cash and cash equivalents | 943 | 475 | 232 | 1,056 | 112 | 2,188 | |||
Receivables | 257 | 177 | 141 | 117 | 75 | 100 | |||
Inventory, net of allowances, customer advances and progress billings | 250 | 266 | 265 | 254 | 280 | 271 | |||
Inventory | 250 | 266 | 265 | 254 | 280 | 271 | |||
Other undisclosed current assets | 946 | 806 | 622 | 365 | 375 | 251 | |||
Total current assets: | 2,396 | 1,725 | 1,260 | 1,792 | 842 | 2,810 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 2,337 | 3,369 | 3,359 | 5,858 | 4,005 | 1,750 | |||
Property, plant and equipment | 441 | 412 | 826 | 772 | 659 | 418 | |||
Long-term investments and receivables | 844 | 871 | 916 | 1,079 | 1,132 | 1,174 | |||
Long-term investments | 844 | 871 | 916 | 1,079 | 1,132 | 1,174 | |||
Intangible assets, net (including goodwill) | 9,564 | 9,768 | 9,972 | 9,975 | |||||
Goodwill | 5,879 | 5,879 | 5,879 | 8,225 | |||||
Intangible assets, net (excluding goodwill) | 3,685 | 3,889 | 4,093 | 1,750 | |||||
Other undisclosed noncurrent assets | 2,172 | 2,172 | 2,172 | ||||||
Total noncurrent assets: | 15,359 | 16,593 | 17,246 | 17,684 | 5,797 | 3,341 | |||
TOTAL ASSETS: | 17,755 | 18,318 | 18,506 | 19,476 | 6,639 | 6,151 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 2,378 | 2,798 | 2,330 | 1,852 | 1,845 | 1,847 | |||
Accrued liabilities | 1,022 | 1,235 | 722 | 591 | 1,202 | 1,221 | |||
Other undisclosed accounts payable and accrued liabilities | 1,356 | 1,563 | 1,608 | 1,261 | 642 | 627 | |||
Deferred revenue | 417 | 513 | 409 | 230 | 161 | 47 | |||
Business combination, contingent consideration, liability | 2,500 | 2,500 | 2,500 | ||||||
Other liabilities | 350 | 350 | 350 | 123 | |||||
Other undisclosed current liabilities | 2,307 | 2,795 | 2,414 | 2,679 | 2,463 | 2,556 | |||
Total current liabilities: | 7,952 | 8,956 | 8,003 | 4,884 | 4,469 | 4,450 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 1,173 | 1,214 | 1,254 | 1,095 | |||||
Long-term debt, excluding current maturities | 1,173 | 1,214 | 1,254 | 1,095 | |||||
Liabilities, other than long-term debt | 7,266 | 8,138 | 8,356 | 13,124 | 3,875 | 1,613 | |||
Deferred income tax liabilities | 2 | 2 | 2 | ||||||
Operating lease, liability | 2,266 | 3,138 | 3,356 | 5,622 | 3,873 | 1,611 | |||
Business combination, contingent consideration, liability | 5,000 | 5,000 | 5,000 | 7,500 | |||||
Total noncurrent liabilities: | 8,439 | 9,352 | 9,610 | 14,219 | 3,875 | 1,613 | |||
Total liabilities: | 16,391 | 18,308 | 17,613 | 19,103 | 8,344 | 6,063 | |||
Equity | |||||||||
Equity, attributable to parent, including: | 1,364 | 10 | 893 | 373 | (1,705) | 88 | |||
Common stock | 0 | 0 | 0 | 0 | 0 | 1 | |||
Additional paid in capital | 55,767 | 52,925 | 52,711 | 56,196 | 52,869 | 52,421 | |||
Accumulated deficit | (61,910) | (59,415) | (57,818) | (55,823) | (54,575) | (52,334) | |||
Other undisclosed equity, attributable to parent | 7,506 | 6,500 | 6,000 | ||||||
Total equity: | 1,364 | 10 | 893 | 373 | (1,705) | 88 | |||
TOTAL LIABILITIES AND EQUITY: | 17,755 | 18,318 | 18,506 | 19,476 | 6,639 | 6,151 |
Income Statement (P&L) ($ in thousands)Annual | Quarterly
9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 1,837 | 1,576 | 1,382 | 975 | 316 | 348 | ||
Cost of revenue | (862) | (850) | (73) | |||||
Cost of goods and services sold | (61) | |||||||
Gross profit: | 975 | 726 | 1,382 | 975 | 316 | 275 | ||
Operating expenses | (2,878) | (1,672) | (2,890) | (1,861) | (2,382) | (2,582) | ||
Operating loss: | (1,903) | (946) | (1,508) | (886) | (2,066) | (2,306) | ||
Nonoperating expense | (342) | (648) | (463) | (360) | (172) | (244) | ||
Interest and debt expense | (40) | (163) | 581 | (352) | (175) | (217) | ||
Loss from continuing operations before equity method investments, income taxes: | (2,286) | (1,758) | (1,391) | (1,599) | (2,413) | (2,767) | ||
Other undisclosed income (loss) from continuing operations before income taxes | 40 | 163 | (581) | 352 | 175 | |||
Loss from continuing operations before income taxes: | (2,245) | (1,595) | (1,972) | (1,247) | (2,238) | (2,767) | ||
Income tax expense | (2) | (23) | (2) | (3) | ||||
Loss from continuing operations: | (2,245) | (1,597) | (1,995) | (1,248) | (2,241) | (2,767) | ||
Other undisclosed net income | 217 | |||||||
Net loss available to common stockholders, diluted: | (2,245) | (1,597) | (1,995) | (1,248) | (2,241) | (2,551) |
Comprehensive Income ($ in thousands)Annual | Quarterly
9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (2,245) | (1,597) | (1,995) | (1,248) | (2,241) | (2,551) | ||
Comprehensive loss, net of tax, attributable to parent: | (2,245) | (1,597) | (1,995) | (1,248) | (2,241) | (2,551) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.